Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 163Breast Neoplasms 123Lung Neoplasms 102Carcinoma, Non-Small-Cell Lung 84Glioblastoma 77Brain Neoplasms 75Neoplasm Metastasis 68Glioma 68Pancreatic Neoplasms 51Neoplasms 45Carcinoma, Renal Cell 45Multiple Myeloma 44Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 39Lymphoma, Large B-Cell, Diffuse 39Carcinoma, Hepatocellular 36Melanoma 35Ovarian Neoplasms 34Lymphoma 34Urinary Bladder Neoplasms 33Astrocytoma 30Sarcoma 26Rectal Neoplasms 26Uterine Cervical Neoplasms 24Oropharyngeal Neoplasms 24Lymphoma, Follicular 24Central Nervous System Neoplasms 24Lymphoma, Non-Hodgkin 23Triple Negative Breast Neoplasms 22Gliosarcoma 22

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2durvalumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Drug Therapy 2Docetaxel 2Disulfides 22C4 antibody 2tucatinib 1tremelimumab 1exemestane 1bintrafusp alfa protein, human 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Magnetic Resonance Spectroscopy × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05710328 2026-05-05

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
235 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡